|
Press Releases |
|
 |
|
Thursday, April 18, 2024 |
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
Wednesday, April 17, 2024 |
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は本日、日本において自社創製の抗てんかん剤「フィコンパ(R)」(一般名:ペランパネル水和物、海外製品名:「Fycompa(R)」)の点滴静注用製剤について新発売したことをお知らせします。 more info >> |
|
Wednesday, April 3, 2024 |
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
Monday, April 1, 2024 |
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
Friday, March 29, 2024 |
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. more info >> |
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture |
Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture. more info >> |
|
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 |
Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ. more info >> |
|
Thursday, March 21, 2024 |
|
Lifenet and Eisai Co-Develop Dementia Insurance "be" |
LIFENET INSURANCE COMPANY and Eisai Co., Ltd. announced today that they have co-developed Dementia Insurance "be", a dementia insurance that supports early detection and treatment of dementia and mild cognitive impairment (hereafter, "MCI") as one of the initiatives under the capital and business alliance agreement concluded in August 2022 for collaboration in dementia and other areas. more info >> |
|
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace |
Eisai Co., Ltd. announced today that it has been selected for the first time by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as one of the Nadeshiko Brand 2024, as a listed company excelling in the promotion of women in the workplace. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully
May 28, 2025 23:29 HKT/SGT
|
|
|
Global Leaders Gather for XIII International Meeting on International Cooperation
May 28, 2025 21:30: JST
|
|
|
Modern Dental Group's Thai Subsidiary Hexa Ceram Held 30th Anniversary Celebration and Dental Symposium
May 28, 2025 21:30 HKT/SGT
|
|
|
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully
May 28, 2025 20:57: JST
|
|
|
Global Leaders Gather for XIII International Meeting on International Cooperation
May 28, 2025 20:30 HKT/SGT
|
|
|
SAPPE Makes a Global Splash in the Beverage Market, Unveils Global Campaign "Life's too Short, You Gotta Chew" at THAIFEX - ANUGA ASIA 2025
May 28, 2025 18:00 HKT/SGT
|
|
|
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 28, 2025 17:45 JST
|
|
|
現代牙科集團泰國公司Hexa Ceram舉辦三十周年慶典暨牙科論壇
May 28, 2025 16:30 HKT/SGT
|
|
|
现代牙科集团泰国公司Hexa Ceram举办三十周年庆典暨牙科论坛
May 28, 2025 16:12 HKT/SGT
|
|
|
三菱重工、2024事業計画推進状況について発表
May 28, 2025 16:05: JST
|
|
|
GK Software becomes a Fujitsu company
May 28, 2025 15:33 JST
|
|
|
GMG Announces Internal G(R) Lubricant Testing Results Showing 10% Fuel Savings and 33% Reduction in Particulate Emissions
May 28, 2025 08:29 HKT/SGT
|
|
|
Spotlight: Sunny Nandwani, Founder & CEO, Acuver Consulting Inc.
May 27, 2025 22:30 HKT/SGT
|
|
|
聯想控股旗下君聯資本及聯想之星共同投資企業派格生物醫藥在港交所成功上市
May 27, 2025 22:10 HKT/SGT
|
|
|
联想控股旗下君联资本及联想之星共同投资企业派格生物医药在港交所成功上市
May 27, 2025 21:41 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|